Akeso

This trial is testing an experimental drug called AK139, given as an injection, in people with chronic sinusitis and nasal polyps—growths in the nose that block airflow. The study compares AK139 against a placebo, with all participants also using a standard steroid nasal spray. T…

This phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) …

This study tests a new drug called AK146D1, given alone or with another drug (AK112), in people with advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if the treatment is safe and can shrink tumors. About 132 adults aged 18-75 with measurable tumors and…

This early-stage trial tests a new drug called AK150 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors.

This study tests a new drug called AK138D1, given alone or with another drug (ivonescimab), in people with advanced breast cancer. The goal is to see if the treatment is safe and can shrink tumors. About 286 adults aged 18 to 75 will take part. This is an early-stage trial, so th…

This Phase 2 study tests a new biologic drug called AK139 in 168 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. Participants will receive either AK139 or a placebo by injection. The study aims to see if AK139 can safely clear skin and …

This study compares two ways of giving the immunotherapy drug AK104 alongside standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. One group gets AK104 as a shot under the skin (subcutaneous), the other as a…

This Phase 2 study tests a new drug called AK139 in 160 people with moderate to severe asthma. Participants receive either AK139 or a placebo by injection under the skin. The trial measures changes in lung function and asthma control over time, while also checking for side effect…

This study tests a combination of two experimental treatments—AK112 (given through a vein) and VG2025 (injected directly into liver tumors)—in 72 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to prior therapy. The goal is to see if the c…

This Phase 1 trial tests a new drug called AK152 in healthy volunteers and people with Alzheimer's disease. The main goal is to check if it is safe and tolerable, and to see how the body processes it. The study is small and early-stage, so it will not prove whether the drug works…

This study tests a drug called AK112 in 60 people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has specific genetic changes and has stopped responding to previous targeted therapy. The main goal is to see how many patients' tumors shr…

This study tests a new medicine called AK139 for people with moderate to severe seasonal allergic rhinitis (hay fever). About 111 adults aged 18-65 with at least a 2-year history of seasonal allergies will receive either AK139 or a placebo. The main goal is to see if AK139 reduce…

This study checks whether AK104, an experimental cancer drug, behaves the same in the body when made at a new manufacturing site versus the original site. It involves 158 healthy Chinese men who will get a single low dose of the drug. The goal is to compare drug levels in the blo…